Insider Selling: Liquidia (NASDAQ:LQDA) Insider Sells $207,932.48 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 7,301 shares of Liquidia stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $28.48, for a total value of $207,932.48. Following the completion of the transaction, the insider owned 177,957 shares in the company, valued at $5,068,215.36. This trade represents a 3.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jason Adair also recently made the following trade(s):

• On Friday, August 21st, Jason Adair sold 73,631 shares of Liquidia stock. The stock was sold at an average price of $69.09, for a total transaction of $5,087,165.79.
• On Monday, July 27th, Jason Adair sold 688 shares of Liquidia stock. The shares were sold at an average price of $87.53, for a total value of $60,220.64.

Liquidia Stock Up 2.5%

Liquidia stock opened at $34.78 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. Liquidia Corporation has a 1-year low of $21.94 and a 1-year high of $93.61. The company has a market cap of $3.11 billion, a PE ratio of 24.77 and a beta of 0.61. The stock’s 50 day moving average price is $61.21 and its 200 day moving average price is $61.73.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). The company had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%. Liquidia’s revenue for the quarter was up 1842.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.49) earnings per share. On average, sell-side analysts predict that Liquidia Corporation will post 2.05 EPS for the current fiscal year.

Hedge Funds Weigh In On Liquidia

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE boosted its position in Liquidia by 18.7% during the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after purchasing an additional 360,372 shares in the last quarter. Eversept Partners LP grew its holdings in Liquidia by 33.0% in the first quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock valued at $25,565,000 after purchasing an additional 167,949 shares during the last quarter. Pale Fire Capital SE increased its position in shares of Liquidia by 2.4% in the first quarter. Pale Fire Capital SE now owns 388,377 shares of the company’s stock valued at $14,657,000 after buying an additional 8,985 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Liquidia in the second quarter valued at $29,694,000. Finally, Seven Fleet Capital Management LP increased its position in shares of Liquidia by 25.2% in the second quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock valued at $20,459,000 after buying an additional 51,727 shares in the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Royal Bank Of Canada set a $65.00 price objective on shares of Liquidia in a research note on Thursday. Jefferies Financial Group upgraded shares of Liquidia to a “strong-buy” rating in a research report on Thursday, October 1st. Piper Sandler set a $129.00 target price on shares of Liquidia in a research report on Friday, July 24th. HC Wainwright increased their target price on shares of Liquidia from $58.00 to $65.00 and gave the company a “buy” rating in a report on Thursday. Finally, Wells Fargo & Company increased their target price on shares of Liquidia from $30.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Liquidia has a consensus rating of “Hold” and a consensus target price of $72.85.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia settled all six patent and antitrust disputes with United Therapeutics for a net $380.7 million, allowing continued commercialization of YUTREPIA for pulmonary arterial hypertension. Ending the litigation removes significant legal uncertainty and avoids a potentially market-disrupting appeal. Liquidia shares surge as settlement ends United Therapeutics litigation
• Positive Sentiment: Analyst sentiment improved after the settlement. LifeSci Capital upgraded LQDA to “outperform” with a $59 price target, while HC Wainwright raised its target to $65 and initiated or reiterated a “buy” rating. BTIG also upgraded the stock to “buy” with a $70 target. LifeSci Capital upgrades Liquidia
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were reported at $222.7 million. Management expects existing cash and ongoing sales to fund the settlement and planned clinical programs without requiring additional financing, supporting the investment case if commercial momentum continues.
• Positive Sentiment: Trading activity reflected renewed speculative interest, with call-option volume more than doubling its typical level. This suggests some traders are positioning for additional gains following the legal resolution.
• Neutral Sentiment: Multiple executives and insiders, including the CEO and CFO, sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax obligations on vested equity awards. Because the transactions were planned and sellers retained substantial holdings, they are a limited standalone signal of sentiment. Liquidia insider sale filing
• Negative Sentiment: The $380.7 million settlement will require $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to antitrust litigation. These payments could materially reduce Liquidia’s cash cushion and constrain future investment.
• Negative Sentiment: Liquidia agreed not to appeal the infringement ruling and will remove the PH-ILD indication from YUTREPIA’s label, narrowing the drug’s addressable market. Needham lowered its price target to $58, despite maintaining a “buy” rating, highlighting ongoing execution and valuation risks.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).